In September 2009, a live attenuated herpes zoster vaccine (ZVL) was made available for out-of-pocket purchase in Canada. Subsequently, in September 2016, ZVL was made available to all Ontario residents aged 65 to 70 through a publicly funded immunization program.
This study evaluates the impact of both the private ZVL availability and the introduction of a publicly funded immunization program on the burden of herpes zoster among Ontario residents aged 65 to 70.
Access the full article and associated resources:
